menu
    • menu
    [{"orgOrder":0,"company":"Rakuten Medical","sponsor":"The National Cancer Center Japan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"ASP-1929","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ The National Cancer Center Japan","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ The National Cancer Center Japan"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Cetuximab-conjugated IRDye700DX","moa":"ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ Merck"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Rakuten Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Cetuximab-conjugated IRDye700DX","moa":"ErbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ Rakuten Medical","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ Rakuten Medical"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cetuximab-conjugated IRDye700DX","moa":"ErbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rakuten Medical \/ Not Applicable"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cetuximab-conjugated IRDye 700DX","moa":"ErbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rakuten Medical \/ Not Applicable"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Momentum Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Series D Financing","leadProduct":"Cetuximab Sarotalocan Sodium","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Rakuten Medical","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Rakuten Medical \/ Momentum Capital Markets","highestDevelopmentStatusID":"12","companyTruncated":"Rakuten Medical \/ Momentum Capital Markets"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Shimadzu","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ASP-1929 Photoimmunotherapy","moa":"ErbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rakuten Medical \/ Shimadzu","highestDevelopmentStatusID":"8","companyTruncated":"Rakuten Medical \/ Shimadzu"},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Cetuximab Sarotalocan Sodium","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rakuten Medical \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Medical \/ Hikma Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Rakuten Medical

    Menu

    Rakuten Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab Sarotalocan Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the...

                            Details : Under the terms of the agreement, Hikma has an exclusive license to commercialize products in Rakuten Medical's pipeline using its photoimmunotherapy technology platform, Alluminox™, in all its MENA markets.

                            Brand Name : ASP-1929

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 10, 2023

                            Lead Product(s) : Cetuximab Sarotalocan Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASP-1929 Photoimmunotherapy

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Shimadzu

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rakuten Medical and Shimadzu Enroll First Patient in the U.S. Clinical Trial of Photoimmunotherapy

                            Details : The trial conducted for ASP-1929 photoimmunotherapy with fluorescence imaging, an antibody-dye conjugate binds to epidermal growth factor receptor, will assess efficacy and safety of surgical tumor resection in patients with operable primary or recurrent...

                            Brand Name : ASP-1929

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 15, 2022

                            Lead Product(s) : ASP-1929 Photoimmunotherapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Shimadzu

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab Sarotalocan Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Momentum Capital Markets

                            Deal Size : $166.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Rakuten Medical, Inc. Closes $166 Million Series D Financing led by General Catalyst

                            Details : Rakuten Medical is conducting a global Phase 3 multi-center clinical trial with ASP-1929 IV Infusion (cetuximab sarotalocan sodium) in patients with recurrent head and neck squamous cell carcinoma.

                            Brand Name : Akalux

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 28, 2021

                            Lead Product(s) : Cetuximab Sarotalocan Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Momentum Capital Markets

                            Deal Size : $166.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab-conjugated IRDye 700DX

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rakuten Medical Publishes Data from Phase I study of RM-1929 Photoimmunotherapy in Recurrent Head and Neck Squ...

                            Details : The data concluded that RM-1929 photoimmunotherapy showed a manageable safety profile in rHNSCC and showed tumor response in the heavily pre-treated patient population was clinically meaningful and warranted further investigation.

                            Brand Name : RM-1929

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 08, 2021

                            Lead Product(s) : Cetuximab-conjugated IRDye 700DX

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab-conjugated IRDye700DX,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rakuten Medical Enrolls First Patient in the U.S. For ASP-1929 in Combination with Anti-PD1 Therapy, for Head ...

                            Details : The trial will enroll three cohorts of patients within distinct populations. Primary endpoints of this study include safety, tolerability, and tumor response of the ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy.

                            Brand Name : ASP-1929

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 23, 2020

                            Lead Product(s) : Cetuximab-conjugated IRDye700DX,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab-conjugated IRDye700DX

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Medlight SA

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Rakuten Medical Announces Acquisition of Medlight SA

                            Details : IlluminoxTM technology platform developed ASP-1929 which binds to epidermal growth factor receptors (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck cancer, esophageal cancer, lung cancer, colon cancer, and pa...

                            Brand Name : ASP-1929

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 19, 2020

                            Lead Product(s) : Cetuximab-conjugated IRDye700DX

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Medlight SA

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cetuximab-conjugated IRDye700DX

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Rakuten Medical Closes Deal with Merck KGaA, Darmstadt to Receive Cetuximab for Production of its ASP-1929 An...

                            Details : Under this agreement, Rakuten Medical may use cetuximab to produce ASP-1929 for clinical trials and commercial sales.

                            Brand Name : ASP-1929

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 07, 2020

                            Lead Product(s) : Cetuximab-conjugated IRDye700DX

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Rakuten Medical

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASP-1929

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : The National Cancer Center Japan

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rakuten Medical Establishes Illuminox™ Alliance Institutes to Accelerate Development of Cancer Therapies

                            Details : Under the signed MOU, NCC and Rakuten Medical will pursue multiple avenues to advance Illuminox-based cancer therapies. NCC will designate a lead principal who will act as an Illuminox Advisor.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 29, 2020

                            Lead Product(s) : ASP-1929

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : The National Cancer Center Japan

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth